The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approaches - 15/02/21
Abstract |
In the past few decades, immunotherapy has emerged as an effective therapeutic option for patients with cutaneous T cell lymphoma (CTCL). CTCL is characterized by progressive impairment of multiple arms of the immune system. Immunotherapy targets these deficits to stimulate a more robust antitumor response, thereby both clearing the malignant T cells and repairing the immune dysfunction. By potentiating rather than suppressing the immune system, immunotherapy can result in longer treatment responses than alternatives such as chemotherapy. In recent years, advances in our understanding of the pathogenesis of CTCL have led to the development of several new agents with promising efficacy profiles. The second article in this continuing medical education series describes the current immunotherapeutic options for treatment of CTCL, with a focus on how they interact with the immune system and their treatment outcomes in case studies and clinical trials. We will discuss established CTCL immunotherapies, such as interferons, photopheresis, and retinoids; emerging therapies, such as interleukin-12 and Toll-like receptor agonists; and new approaches to targeting tumor antigens and checkpoint molecules, such as mogamulizumab, anti–programmed cell death protein 1, anti-CD47, and chimeric antigen receptor T cell therapy. We also describe the principles of multimodality immunotherapy and the use of total skin electron beam therapy in such regimens.
Le texte complet de cet article est disponible en PDF.Key words : CTCL, cutaneous T cell lymphoma, dermatologic oncology, drug response, immune deficiency, immunopathogenesis, immunotherapy, mycosis fungoides, Sézary syndrome
Plan
Mr Weiner and Mr Durgin contributed equally to this work. |
|
Funding sources: Mr Durgin is supported by National Center for Advancing Translational Sciences grant number TL1TR001880. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. |
|
Disclosure: Drs Wysocka and Rook are inventors on a pending patent for the use of resiquimod for cutaneous T cell lymphoma. |
|
IRB approval status: Not applicable. |
|
Date of release: March 2021. |
|
Expiration date: March 2024. |
Vol 84 - N° 3
P. 597-604 - mars 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?